BOC Hong Kong (Holdings) Limited (CU9.F)
| Previous Close | 2.7800 |
| Open | 2.8800 |
| Bid | 2.8000 x N/A |
| Ask | 3.0200 x N/A |
| Day's Range | 2.8000 - 2.8800 |
| 52 Week Range | 2.0400 - 2.8800 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksBeat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
ZacksHere's What Could Help BOC Hong Kong (BHKLY) Maintain Its Recent Price Strength
BOC Hong Kong (BHKLY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
South China Morning PostWealthy clients turn to HSBC, Manulife, Bank of China amid heightened interest in Hong Kong's cash-for-residency scheme
Hong Kong's leading banking and finance firms are being bombarded with inquiries related to a cash-for-residency scheme since its launch on March 1. HSBC, Bank of China (Hong Kong) (BOCHK), Manulife and Everbright Securities International are among those that have seen heightened interest in products from prospective clients under the revamped Capital Investment Entrant Scheme (CIES). InvestHK, which is responsible for assessing whether the applications fulfil the financial requirements under th
